Physician profile
Spiro P Combest
NPI 1194934216
$2,264.22
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $178 · 2021: $141 · 2022: $483 · 2023: $616 · 2024: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $452.28 | 2019-2024 | Lensx, Clareon, Eysuvis |
| Abbvie INC. | $434.67 | 2022-2024 | Durysta |
| Sun Pharmaceutical Industries INC. | $302.57 | 2019-2024 | Cequa |
| Bausch & Lomb Americas INC. | $137.24 | 2022-2024 | Ic-8 Apthera Iol, Xiidra, Prolensa |
| Novartis Pharmaceuticals Corporation | $132.51 | 2020-2023 | |
| Kala Pharmaceuticals, INC. | $120.41 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $116.58 | 2020-2023 | Acuvue |
| Rayner Intraocular Lenses Limited | $82.90 | 2022-2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Oyster Point Pharma, INC. | $78.12 | 2022-2023 | Tyrvaya |
| Allergan, INC. | $66.98 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $53.03 | 2024 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $39.32 | 2019-2021 | |
| Dompe US, INC. | $37.62 | 2022-2023 | Oxervate |
| Glaukos Corporation | $33.33 | 2024 | Idose |
| Sight Sciences, INC. | $24.59 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $23.89 | 2023 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.76 | 2019 | |
| Biotissue Holdings INC. | $20.57 | 2022 | |
| Janssen Biotech, INC. | $19.06 | 2024 | Stelara |
| Amgen INC. | $17.26 | 2024 | Tepezza |
| Coopervision INC. | $16.95 | 2023 | Myday Contact Lens |
| Horizon Therapeutics Plc | $16.42 | 2023 | Tepezza |
| Ocular Therapeutix, INC. | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spiro Combest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.